TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35413886
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 1.5-g meropenem resolved in 30-ml saline given via central line for 30 min, followed by 0.75-g meropenem every 8 h for 30 min.
Study: 35413886
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 1.5-g meropenem.
Study: 34441930
Drug: Immediate invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate invasive treatment strategy (<3 h)
Study: 34441930
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive treatment strategy (12–24 h)
Study: 35667715
Drug: Cevira (hexaminolevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevira (hexaminolevulinate photodynamic therapy)
Study: 34351693
Drug: Intralesional tuberculin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional tuberculin immunotherapy
Study: 33942655
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapies
Study: 33665467
Drug: Personalized antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antibiotic prescription feedback and evidence-based treatment guidelines including region-specific antibiotic resistance information, provided quarterly for two years.
Study: 33665467
Drug: Personalized antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antibiotic prescription feedback and evidence-based treatment guidelines.
Study: 32579859
Drug: Conventional voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional voice therapy
Study: 33767062
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy (e.g., percutaneous coronary intervention or coronary artery bypass graft)
Study: 36444331
Drug: Atorvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin therapy
Study: 35588754
Drug: Single vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccine regimen (Rotavac-Rotavac-Rotavac, Rotasiil-Rotasiil-Rotasiil)
Study: 35588754
Drug: Single vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccine regimen
Study: 34625284
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg/day
Study: 32627500
Drug: Naomaitai Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naomaitai Capsules
Study: 32627500
Drug: Xiaoshuan Changrong
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoshuan Changrong Capsules
Study: 32627500
Drug: Angong Niuhuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angong Niuhuang Pills
Study: 32627500
Drug: Naoxintong Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxintong Capsules
Study: 32627500
Drug: Tongxinluo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo Capsules
Study: 32627500
Drug: Naoxueshu Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxueshu Oral Liquid
Study: 32627500
Drug: Zhuyu Tongmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuyu Tongmai Capsules
Study: 32627500
Drug: Yinxingye Tablets
Normalized name: Yinxingye
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinxingye Tablets
Study: 32627500
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen Tablets
Study: 33779002
Drug: S(+)-ibuprofen (S-IBU)
Normalized name: ibuprofen Oral Tablet [Ibu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)-ibuprofen (S-IBU)
Study: 33779002
Drug: R(−)-ibuprofen (R-IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: R(−)-ibuprofen (R-IBU)
Study: 32736660
Drug: Treatment-as-usual (control)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (control)
Study: 32658077
Drug: Neoadjuvant Stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Stereotactic Body Radiation Therapy (SBRT) - 33 Gy in 5 fractions to gross tumor plus abutting vessel, with or without 25 Gy in 5 fractions to pancreatic head/body and celiac/superior mesenteric artery.
Study: 32658077
Drug: Fractionated Chemoradiation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated Chemoradiation - 50.4 Gy in 28 fractions to gross tumor, superior mesenteric/celiac arteries, and enlarged lymph nodes with concurrent bolus 5‐FU, leucovorin, oxaliplatin, irinotecan or gemcitabine/nab‐paclitaxel.
Study: 32658077
Drug: Neoadjuvant Stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Stereotactic Body Radiation Therapy (SBRT)
Study: 34658960
Drug: Smartphone-based, multi-domain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based, multi-domain cognitive training with gamified elements together with treatment as usual (TAU)
Study: 38869034
Drug: Short-term dual
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term dual antiplatelet therapy (DAPT)
Study: 35362188
Drug: Corticosteroid plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid plus glycyrrhizin (48-week stepwise dose reduction of methylprednisolone plus glycyrrhizin)
Study: 32438483
Drug: Telemonitoring (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring (daily body weight measurement, daily recording of HF symptoms, and personalised education)
Study: 36335552
Drug: Medicinal cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicinal cannabis (MC) as a prescription-only medication
Study: 35302210
Drug: Ketamine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2.0 mg/kg (K2 group)
Study: 36193903
Drug: 12-week tele-exercise
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week tele-exercise training program (3 sessions/week, 30 min/session, weekly remote monitoring)
Study: 34032504
Drug: Intermittent Androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Androgen Deprivation Therapy (IADT)
Study: 36067985
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (education on nutrition, oral hygiene, and child stimulation)
Study: 35775631
Drug: Curcumin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin treatment (200 mg twice daily for 6 weeks)
Study: 35775631
Drug: Curcumin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin treatment
Study: 35446936
Drug: Eltrombopag (ELTR)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag (ELTR) combined with immunosuppressive therapy (IST)
Study: 35446936
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy (IST) alone
Study: 35446936
Drug: Eltrombopag (ELTR)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag (ELTR) combined with immunosuppressive therapy (IST) in SAA
Study: 35446936
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy (IST) alone in SAA
Study: 35446936
Drug: Eltrombopag (ELTR)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag (ELTR) combined with immunosuppressive therapy (IST) in vSAA
Study: 35446936
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy (IST) alone in vSAA
Study: 33462752
Drug: Entrectinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrectinib (600 mg research formulation)
Study: 33462752
Drug: Entrectinib (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrectinib (100-400 mg/m2, and 600-800 mg) once daily with food
Study: 33462752
Drug: Entrectinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrectinib (600 mg single doses, fasted state)
Study: 32460816
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy (NET) with goserelin and tamoxifen for 24 weeks
Study: 33681738
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg
Study: 34782125
Drug: Population-wide metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Population-wide metformin therapy
Study: 37266947
Drug: Low-Molecular-Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Molecular-Weight Heparin (LMWH)
Study: 33156289
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UH)
Study: 37271356
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (OMT) alone
Study: 34053111
Drug: Cracked corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cracked corn (CC: 74% NSC & 9% CP)
Study: 34053111
Drug: Low NSC
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low NSC pellet (L-NSC: 6% NSC & 12% CP)
Study: 33002071
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP target < 140 mmHg)
Study: 32216011
Drug: Vericiguat 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 10.0 mg
Study: 35818134
Drug: TAC/Collagen gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC/Collagen gel
Study: 34428980
Drug: BGF 320/18/9.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF 320/18/9.6 µg
Study: 34428980
Drug: BGF 160/18/9.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF 160/18/9.6 µg
Study: 34428980
Drug: GFF 18/9.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF 18/9.6 µg
Study: 34428980
Drug: BFF 320/9.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFF 320/9.6 µg
Study: 32444980
Drug: FSRS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSRS plus BEV-based chemotherapy
Study: 32444980
Drug: BEV-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEV-based chemotherapy alone
Study: 32781457
Drug: 2.5‐mg hypobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5‐mg hypobaric bupivacaine alone
Study: 32781457
Drug: 2.5‐mg hypobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5‐mg hypobaric bupivacaine and 10‐μg fentanyl
Study: 32781457
Drug: 2.5‐mg hypobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5‐mg hypobaric bupivacaine and 0.5‐mg morphine
Study: 32048900
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment plus PSD
Study: 32994242
Drug: Metformin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (various dosages)
Study: 34207870
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (esomeprazole 40 mg, amoxicillin 1 gr, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days)
Study: 34207870
Drug: Tailored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapy based on antimicrobial susceptibility testing
Study: 33039650
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU vitamin E and/or 20 μg selenium daily
Study: 37318667
Drug: 650 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 nm low-level red light (LLRL) irradiation for 6 min daily
Study: 34716791
Drug: High polyphenol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High polyphenol olive oil (HPOO) 60 mL/day (320 mg/kg polyphenols)
Study: 34716791
Drug: Low polyphenol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low polyphenol olive oil (LPOO) 60 mL/day (86 mg/kg polyphenols)
Study: 35107389
Drug: Standard antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiviral therapy
Study: 34714720
Drug: Quadrivalent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent high-dose inactivated influenza vaccine (IIV4-HD)
Study: 34714720
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (IIV4-HD and IIV4-SD)
Study: 33473017
Drug: Standard supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supportive treatment
Study: 35699175
Drug: Genotype-guided selection
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided selection of antiplatelet therapy after PCI
Study: 35699175
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with clopidogrel
Study: 33450486
Drug: Intermittent low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermittent low-dose esomeprazole (40 mg once a day for 8 weeks)
Study: 33450486
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose esomeprazole (40 mg once a day for 8 weeks)
Study: 33450486
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose esomeprazole
Study: 34377044
Drug: TDT 064
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDT 064 (topical agent)
Study: 34321051
Drug: Short-term mentalisation-based
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term mentalisation-based therapy (20 weeks)
Study: 34321051
Drug: Long-term mentalisation-based
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term mentalisation-based therapy (14 months)
Study: 37853163
Drug: Oral intubation
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intubation
Study: 32495059
Drug: Intravitreal anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal anti-VEGF injection (bevacizumab or ranibizumab)
Study: 32495059
Drug: Intravitreal anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal anti-VEGF injection (bevacizumab) in HTG
Study: 35081280
Drug: TNF inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitor
Study: 33040012
Drug: Health-RESPECT intervention
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-RESPECT intervention involving comprehensive geriatric assessment, individualised care plan, medication and rehabilitation management, periodic video-conference, and in-system assessment.
Study: 34503290
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (two doses)
Study: 36216679
Drug: BNT162b2 booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 booster dose
Study: 33998206
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of TXA (15 mg/kg) 30 minutes before operation (Group A)
Study: 33998206
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of TXA (1 g injected into the medullary cavity after proximal femur grooving) (Group B)
Study: 33998206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but can be inferred as no TXA administration)
Study: 33414363
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavior therapy (TF-CBT)
Study: 36316078
Drug: Complex multidisciplinary
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex multidisciplinary intervention to improve initial medication adherence (IMA)
Study: 32304981
Drug: Intramuscular or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular or intranasal administration of naloxone
Study: 32202124
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling combined with manual therapy (DN+MT)
Study: 36533622
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment alone
Study: 34529156
Drug: Nasal corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal corticosteroid (NC) therapy + normal saline solution (NSS) administered twice a day (Group 2)
Study: 34529156
Drug: Nasal corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal corticosteroid (NC) therapy only (Group 1)
Study: 37626292
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol
Study: 34379922
Drug: Cabotegravir (CAB-LA)
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabotegravir (CAB-LA) 600 mg intramuscularly every 8 weeks
Study: 34379922
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) daily
Study: 36375487
Drug: Control (Proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Proton Pump Inhibitor - Lansoprazole)
Study: 35677096
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug therapy
Study: 34314240
Drug: Transurethral Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral Water Vapor Therapy (TWVT)
Study: 34257042
Drug: Budesonide prophylaxis
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide prophylaxis (3 mg PO daily at day +5 post‐AHCT till discharge)
Study: 36611211
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition
Study: 32085844
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (specifically amino acids)
Study: 32783769
Drug: Essen group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essen group (control vaccine)
Study: 34024173
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 × 150 mg caffeine daily for 10 days)
Study: 34879822
Drug: Low mean
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low mean arterial pressure (L-MAP) group
Study: 32616026
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of antibiotics at anesthesia induction (n = 73)
Study: 33586174
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (no treatment)
Study: 33010188
Drug: Ustekinumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (6 mg/kg intravenously at week 0, followed by 90 mg subcutaneously every 8 weeks)
Study: 35412513
Drug: No-pill control
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-pill control (NPC)
Study: 33713742
Drug: Cisplatin at
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at 40 mg/m²
Study: 32321651
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (TRPMS)
Study: 36889611
Drug: Therapeutic-dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose enoxaparin and therapeutic-dose apixaban
Study: 34781363
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg daily
Study: 33611431
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy plus cTACE (arm A)
Study: 32676980
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living
Study: 32079557
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy
Study: 34175857
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 0.3 mg/kg
Study: 37093712
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg subcutaneously
Study: 37059702
Drug: Perampanel 8
Normalized name: perampanel 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 8 mg/day
Study: 35042057
Drug: Talus mobilization-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talus mobilization-based manual therapy (six sessions of anteroposterior talus mobilization)
Study: 32922827
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (control group)
Study: 32961410
Drug: Oxytocin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (24 IU intranasal)
Study: 36455187
Drug: Decitabine (DAC)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (DAC) 20 mg/m2/d days 1‐5
Study: 36455187
Drug: Hydroxyurea (HY)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HY) 1‐4 g/d
Study: 34331258
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg
Study: 35526605
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg dose, oral)